References
- Goa K L, Ward A. Buspirone. A preliminary review of its pharamacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114–29
- Sanghera M K, McMillen B A, German D C. Buspirone, a nonbenzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. European J Pharmacol 1983; 86: 107–10
- Trulson M E, Henderson L J. Buspirone increases locus coeruleus noradrenergic neuronal activity in vitro. European J Pharmacol 1985; 106: 195–7
- Charney D S, Heninger G R, Breier A. Noradrenergic function in panic anxiety. Arch Gen Psychiatry 1984; 41: 751–63
- Stone E A. Adaptation to stress and brain noradrenergic receptors. Neurosci Biobehav Rev 1983; 7: 503–9
- Eison A S, Temple D L. Buspirone: Review of its pharmacology and current perspectives in its mechanism of action. AM J Med 1986; 80: 1–9
- Riblet L A, Taylor D P, Eison M S, Stanton B C. Pharmacology and neurochemistry of buspirone. J Cün Psychiatry 1982; 43: 11–6
- McMillen B A. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission. J Neural Transmission 1985; 64: 1–12
- Garattini S, Caccia S, Mennini T. Notes on buspirone's mechanisms of action. J Clin Psychiatry 1982; 43: 19–22
- Lazareno S, Marriott D B, Nahorski S R. Differential effects of selective and non-selective neuroleptics on intracellular and extracellular cyclic AMP accumulation in rat striatal slices. Brain Research 1985; 361: 91–8
- Bylund D B, Snyder S H. Beta-adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 1976; 12: 568–80
- Cohen R M, Aulakh C S, Campbell I C, Murphy D L. Functional subsensitivity of alpha2-adrenoceptors accompanies reductions in yohimbine binding after clorgyline treatment. European J Pharmacol 1982; 81: 145–8